Efficacy of ALK5 inhibition in myelofibrosis

Myelofibrosis (MF) is a bone marrow disorder characterized by clonal myeloproliferation, aberrant cytokine production, extramedullary hematopoiesis, and bone marrow fibrosis. Although somatic mutations in JAK2, MPL, and CALR have been identified in the pathogenesis of these diseases, inhibitors of t...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:JCI Insight
Glavni autori: Yue, Lanzhu, Bartenstein, Matthias, Zhao, Wanke, Ho, Wanting Tina, Han, Ying, Murdun, Cem, Mailloux, Adam W., Zhang, Ling, Wang, Xuefeng, Budhathoki, Anjali, Pradhan, Kith, Rapaport, Franck, Wang, Huaquan, Shao, Zonghong, Ren, Xiubao, Steidl, Ulrich, Levine, Ross L., Zhao, Zhizhuang Joe, Verma, Amit, Epling-Burnette, Pearlie K.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Clinical Investigation 2017
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5374075/
https://ncbi.nlm.nih.gov/pubmed/28405618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.90932
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items